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Abstract
Senescence is a cellular stress response triggered by diverse stressors, including oncogene activation, where it serves as a 
bona-fide tumour suppressor mechanism. Senescence can be transmitted to neighbouring cells, known as paracrine secondary 
senescence. Secondary senescence was initially described as a paracrine mechanism, but recent evidence suggests a more 
complex scenario involving juxtacrine communication between cells. In addition, single-cell studies described differences 
between primary and secondary senescent end-points, which have thus far not been considered functionally distinct. Here 
we discuss emerging concepts in senescence transmission and heterogeneity in primary and secondary senescence on a 
cellular and organ level.
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Introduction
Cellular senescence is a stress response programme that irre-
versibly and stably arrests the cell cycle following a variety 
of intrinsic and extrinsic stressors such as shortening of the 
chromosomal termini, DNA damage, oxidative stress, onco-
genic and mitogenic stimuli [1–3]. Cellular senescence was 
first described by Hayflick and Moorhead, who observed that 
cultured human fibroblasts undergo a finite number of cell 
divisions, a phenomenon later widely known as the ‘Hayflick 
limit’ and termed as replicative senescence [4]. The limited 
replicative capacity of cells in vitro spontaneously suggests 
a model for ageing at the cellular level. It is now clear that 
this proliferative arrest is mainly driven by telomere attrition 
[5]. Initially dismissed as an in vitro artefact that bore no 
relevance to biological mechanisms in vivo, the concept of 
cellular senescence has stood the test of the past five decades 
and evolved to become relevant beyond the ageing context, 
with critical physiological functions in preventing tumour 
formation, remodelling of tissues during embryonic devel-
opment, and promoting wound healing and immunogenic 
clearance [6].
In the replicative senescence model of proliferating 
human cells, successive telomere erosion in each cell divi-
sion ultimately uncaps the free double-stranded chromosome 
ends, causing them to be recognised as DNA double-strand 
breaks (DSBs) and activating the DNA damage response 
(DDR) pathway [7, 8]. The telomere dysfunction-initiated 
DDR signalling engages the ataxia telangiectasia-mutated 
(ATM) kinase that subsequently stabilises the tumour 
suppressor protein 53 (TP53), leading to an upregulation 
of its target the cyclin-dependent kinase (Cdk) inhibitor 
(CDKN1A). The TP53/CDKN1A pathway implements a 
cell cycle exit by inhibiting the activity of cyclin E-CDK2 
and allowing the hypophosphorylated form of the retino-
blastoma (RB) tumour suppressor to enable G1 arrest [9]. 
Alternatively, senescence can be established independently 
of the TP53/CDKN1A axis through the p16/RB tumour sup-
pressor pathway. The cyclin dependent kinase inhibitor 2A 
(CDKN2A) locus encodes p16 and ARF, with the former 
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repressing CDK4/6 while the latter cross-talking with the 
TP53/CDKN1A network.
Unlike quiescent or terminally differentiated cells, senes-
cent cells do not respond to mitogenic cues and are not spe-
cialised cells resulting from a developmentally differentiated 
program. Senescent cells display distinguishing characteris-
tics morphologically and biochemically. They are generally 
characterised by an enlarged and flattened shape and robustly 
express the lysosomal enzyme β-galactosidase, detectable by 
senescence-associated b-galactosidase (SA-b-gal) staining at 
sub-optimal pH [10]. Increased levels of p16 are also com-
monly used as a marker of senescence in vitro and in vivo. 
Another prominent feature is the formation of senescence-
associated heterochromatic foci (SAHF), a rearrangement 
of heterochromatin into discrete nuclear subdomains vis-
ible by 4′,6-diamidino-2-phenylindole (DAPI) staining. One 
of the most striking changes associated with senescence is 
the secretion of a suite of pro-inflammatory cytokines and 
chemokines, extracellular matrix proteins, growth factors 
and metalloproteinases as part of a senescence-associated 
secretory phenotype (SASP) [11]. SASP components attract 
immune cells for clearance of senescent cells, ensuring tis-
sue homeostasis. Another emerging fundamental feature 
of senescent cells is accumulation of lipofuscin, insoluble 
granules formed from damaged and cross-linked proteins 
[12]. Lipofuscin accumulation reflects macromolecular 
damage and altered metabolism, both of which have been 
reported as hallmarks of senescence, and has been exploited 
for identification of senescence in vitro and vivo [13, 14] 
as well as proposed as the first screening step in a multi-
marker algorithmic approach for senescent cell detection 
[15]. However, to date, none of the senescence markers are 
absolutely reliable or specific for the in vivo identification 
of all senescence types and different markers must be used 
in combination to conclusively recognise senescent cells. 
Discovering novel senescence biomarkers that are of uni-
versally biological interest is, therefore, an ongoing quest in 
the field. Overall, the most recent consensus from the Inter-
national Cell Senescence Association (ICSA) summarises 
the four interdependent hallmarks of senescence as: (1) cell 
cycle arrest; (2) SASP; (3) macromolecular damage; and (4) 
deregulated metabolism [15].
Oncogene‑induced senescence: primary senescence
Among a plethora of senescence stimuli, intrinsic changes 
from activated oncogenes invoke not only an irreversible 
state of proliferative arrest but also a biologically meaning-
ful response that curbs malignant transformation. This mode 
of senescence is referred to as oncogene-induced senes-
cence (OIS), also considered as primary senescence. The 
first observation of OIS was described when an oncogenic 
form of Ras, HrasV12, was ectopically expressed in primary 
cell culture of human lung fibroblasts IMR90. Senescent 
growth arrest is also stably established in vivo with a notable 
example being the ectopic expression of Ras in mammary 
epithelial cells [16]. In contrast to replicative senescence, 
OIS occurs in a telomere erosion-independent manner and 
can engage both the TP53/CDKN1A and p16/RB networks. 
Other studies have shown that loss of TP53 or its regula-
tor p19 in mice provokes Ras-induced cancer cell invasion, 
while the reactivation of TP53 suppresses tumour growth 
whilst displaying common senescence markers [17–19]. OIS 
cells commonly have increased expression of p16 and can 
escape from senescence and re-enter the cell cycle in the 
event of low p16 levels [20]. The maintenance of OIS is 
dependent upon the accumulation of RB, which acts down-
stream of p16 through repression of E2F-target genes asso-
ciated with DNA replication [21]. Despite much evidence 
on the well-established involvement of TP53 and p16 in 
OIS, in certain cell types and contexts TP53 and p16 are not 
required for the initiation and maintenance of OIS [22, 23]. 
Discordant results were also reported in human mammary 
epithelial cells, which undergo Ras-induced senescence 
without engaging p16 and TP53 [24]. This seems to reflect 
the variability between cell types in undergoing TP53- or 
p16-mediated senescence.
Recent studies have implicated the NOTCH signalling 
pathway as one of the regulators of OIS. NOTCH signal-
ling is an evolutionarily conserved pathway and was first 
described in cell-fate decisions during wing development in 
Drosophila [25]. The canonical NOTCH pathway relies on a 
NOTCH receptor expressed on the signal-receiving cell upon 
direct contact with its ligand on the adjacent signal send-
ing cell. This ligand-receptor interaction eventually leads 
to cleavage of the NOTCH intracellular domain (NICD), 
a constitutively active form of NOTCH, which enters the 
nucleus to bind to a transcriptional complex containing 
Mastermind-like 1 (MAML1) and other factors to activate 
target gene expression. Network enrichment analysis and 
flow cytometry have revealed upregulation of NOTCH1 in 
OIS cells accompanied by induction of transforming growth 
factor-beta (TGFβ) [21]. However, the increased NOTCH 
activity during OIS was only transient while cells transition 
into the early phase of primary OIS. The latter phase of OIS 
establishment saw the return of N1ICD and NOTCH-1 target 
levels to resting activity. Strikingly, similar to oncogenic 
activation, ectopic expression N1ICD was shown to drive 
cell-autonomous senescence, in what is known as Notch-
induced senescence (NIS) or primary NIS, in human fibro-
blasts with a distinct secretory phenotype and chromatin 
structure from that of primary OIS triggered by Ras activa-
tion [26, 27]. For example, primary NIS cells show a reduc-
tion of basal levels of the proinflammatory cytokine IL-8 
and activation of a canonical NOTCH ligand, JAG1, as well 
as TGFβ1, while lacking SAHF formation [26, 27]. Overall, 
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these pioneering studies of NIS clearly demonstrated the 
contribution of NOTCH signalling as a transient component 
of primary senescence. Given the diverse roles of NOTCH 
signalling in development, cell differentiation and cancer, it 
is of fundamental interest to investigate the functional sig-
nificance of NOTCH in senescence, which remains to be 
established.
The physiological role of primary OIS remains clear 
and unequivocal: serving as an early, cell-intrinsic tumour-
suppressive mechanism. Multiple studies in lung and pan-
creas have shown that conditional activation of oncogenic 
 KRASV12 led to neoplastic transformation in pre-malignant 
conditions that were accompanied by senescence mark-
ers [28]. Another in vivo study in mouse lymphoid cells 
demonstrated that NRAS overexpression triggered OIS 
that prevents full lymphoma progression [29]. The tumour-
suppressive role of OIS is also evident in the mouse pros-
tate following depletion of the tumour suppressor PTEN, 
but not when both PTEN and TP53 were lost in advanced 
prostate cancer [30]. Crucially, in vitro and in vivo experi-
ments in human melanocytic naevi (moles) present one of 
the most intriguing findings showing OIS as a barrier to 
tumourigenesis [31]. Up to 80% of these naevi harbour the 
BRAFV600E mutation, the most frequent mutation in mela-
nomas. BRAFV600E-expressing melanocytes persist in the 
growth-arrested state and display several OIS markers such 
as upregulation of p16 and positive SA-β-gal staining [32, 
33]. Still, they retain the ability to transform into malignancy 
if BRAF-induced senescence is silenced or reversed. Naevi 
are therefore benign lesions, that arrest stably for decades 
before the course of melanogenesis takes place, represent-
ing one of the best available examples of OIS in vivo. It 
is therefore of great biological interest to understand the 
tumour suppressor state and its genomic dynamics before 
cells escape from senescence and progress into full-blown 
melanoma. Examples of in vivo OIS are numerous and have 
been extensively reviewed elsewhere [34, 35].
Non‑cell‑autonomous aspects of OIS 
(secondary senescence)
Paracrine transmission of senescence
Paradoxically, the past few years have witnessed conten-
tious challenges to the prevailing function and mechanism 
of OIS, revealing more diverse and sometimes contradic-
tory roles of OIS than previously believed. Far from being a 
simple and terminal state of replicative cessation, OIS cells 
communicate and interact with each other, consistent with 
the fact that OIS cells remain metabolically active. Pioneer-
ing studies showed that OIS cells are able to self-amplify 
expression of their SASP components such as Intereukin 
6/8 (IL-6 and IL-8) alongside other inflammatory molecules 
in an autocrine manner, by reinforced activation of nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-
κB) and CCAAT-enhancer-binding protein beta (C/EBPβ) 
[36, 37]. Subsequent work then described the ability of 
senescent cells to engage in cell-to-cell communication, 
modifying their microenvironment via paracrine signalling 
and establishing a mode of senescence named secondary 
senescence [38]. When co-culturing OIS and proliferating 
cells, OIS cells induced a senescence phenotype in their 
growing neighbouring cells through locally secreted SASP 
molecules [38]. Quantitative proteomics and small-molecule 
inhibitor screens have identified complex inflammasomes 
and secretomes containing transforming growth factor beta 
(TGFβ), vascular endothelial growth factor (VEGF) and 
chemokine CC motif ligand 2 (CCL2) as modulators of 
paracrine senescence. Interleukin 1 (IL-1) signalling was 
further shown to be a key upstream regulator of the proin-
flammatory signalling cascade and inhibition of the NLR 
family pyrin domain containing 3 (NLRP3) inflammasome, 
which regulates IL-1β, led to the suppression of the SASP 
phenotype [38]. Additional findings have also pointed to the 
interplay between DNA damage, oxidative stress and parac-
rine senescence mediated by the release of IL-1 and TGFβ, 
with DDR signalling being shown to induce senescence in 
bystander cells [39].
The SASP secretome, as a mediator of paracrine activi-
ties of OIS, displays complex and dynamic features, part 
of which are regulated by NOTCH signalling [Fig. 1]. By 
comparing the transcriptomes and proteomes of NIS fibro-
blasts to those of the classic primary Ras-induced senes-
cence (RIS), a time-course switch in the SASP-associated 
secretomes was revealed [26]. High levels of NOTCH1 
drove a TGF-β-dominant secretome in the first wave of 
OIS secretion and at the same time inhibited a C/EBPβ-
orchestrated SASP expression. The second wave was char-
acterised by low levels of NOTCH1 and the reliance on C/
EBPβ-dominant expression of proinflammatory cytokines. 
These two biochemically distinct and functionally oppos-
ing secretomes highlight the heterogeneity of SASP during 
the progression of OIS and the possible involvement of its 
spatio-temporal fluctuations in modulating paracrine trans-
mission of senescence. What remain to be determined are 
the factors that control the switch of SASP dynamics and 
their physiological relevance.
As paracrine senescence is consistently observed in 
human and mouse models of OIS [38], the previously unap-
preciated non-cell-autonomous activities of OIS manifest 
a critical link between the expression of SASP factors and 
the induction of paracrine senescence in vivo, with far-
reaching biological implications in determining the cellular 
outcome of normal cells in the context of tumourigenesis. 
By means of secreting SASP factors into the extracellular 
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compartment, not only can OIS cells recruit immune cells 
to eliminate tumour cells [40, 41], but they can also pro-
mote tumourigenesis when physiological conditions become 
unfavourable. In skin, prostate and liver cancer models, the 
SASP phenotype is found to facilitate migration of cancer 
cells or favour an immunosuppressive microenvironment, 
which increases the risk of proliferation, angiogenesis and 
metastasis [42–44]. Taken together, it is becoming increas-
ingly appreciated that OIS possesses a dual role in cancer 
pathogenesis, and this is largely dependent on the tissue con-
text, the composition of the SASP and the duration of the 
senescence state. In this respect, there have been attempts 
to selectively remove non-advantageous senescent cells that 
may adversely transform their surrounding cells into malig-
nant cells without affecting the functionally beneficial senes-
cent cells. This has proved to be a success in a transgenic 
mouse system where p16-expressing senescent cells can be 
selectively eliminated [45]. Clearance of these p16-positive 
cells improved age-associated phenotypes, lifespan and tis-
sue rejuvenation. A follow-up study then confirmed a sig-
nificant reduction of spontaneous tumour formation after 
selective removal of senescent cells [46]. Paradoxically, 
a very recent report has demonstrated a slow process of 
senescence accumulation during a lifespan of p16-knock in 
mice whose p16high hepatic senescence cells appear to have 
important structural and functional roles [47]. Removal of 
liver cells with p16high led to liver and perivascular fibrosis, 
impairing the health of the animals. This suggests that the 
timing of senescence might be a key factor that determines 
the outcome of physiological and pathological conditions. 
Similarly, another observation also showed that C/EBPβ is 
a key player in the TGFβ cytostatic response by regulat-
ing expression of p15Ink4b, which contradicts the notion 
that OIS phase I involves TGFβ but not C/EBPβ [48]. It 
remains to be tested whether such contradictory results are 
physiologically relevant with the paradox observed in the 
elimination of senescent cells.
Hence, the concept of OIS as an in vivo antagonistic plei-
otropy has emerged, featuring an anti-cancer action in early 
stages of oncogenesis and a switch to a deleterious, pro-
cancer phase over time with advanced age. The key ques-
tions now needing answering are when and why exactly the 
twisted turn of senescence occurs. Pivotal to understanding 
the complexity of senescent effects is a comprehensive detail 
of how senescent cells interact with their microenvironment 
through short- and long-term secretion of SASP factors and 
accurate SASP factor composition.
More recently, the paracrine transmission of senescence 
has been found to play a role in cellular reprogramming, 
as shown when SASP components induced senescence and 
encouraged reprogramming by activation of octamer-bind-
ing transcription factor 4 (Oct4), SRY-box 2 (Sox2), Krup-
pel like factor 4 (Klf4) and MYC proto-oncogene, bHLH 
transcription factor (c-Myc) (OSKM or Yamanaka factors) 
in non-senescent cells [49, 50]. These studies collectively 
serve to improve our understanding of the complex network 
Fig. 1  Schematic representation of the dynamic progression of pri-
mary oncogene-induced senescence. Primary OIS cells display two 
main phases, each with distinct a distinct SASP profile. The first or 
early stage of primary OIS is characterised by increased TGFβ sig-
nalling and NOTCH-dominant activity. The second or late stage of 
primary OIS is driven by C/EBPβ-rich and pro-inflammatory factors
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of the SASP, which contains many layers of regulation for 
signal amplification and exploits paracrine mechanisms 
to achieve secondary senescence in the cell neighbour-
hood both in vitro and in vivo. In addition, other modes 
of non-cell-autonomous activities of senescence have been 
described, including direct protein transfer through mem-
brane protrusions connecting two cells called cytoplasmic 
bridges [51] and extracellular vesicles secreted from senes-
cent cells [52, 53].
Juxtacrine transmission of senescence
The molecular basis for controlling secondary senescence 
and the non-cell-autonomous properties of OIS are still 
under active investigation and revision, as the concept of 
secondary senescence is relatively novel and likely to be 
understood not as a static or permanent process, but as a 
highly dynamic and variable outcome depending on hetero-
geneous SASP secretomes. Coming into play is the contri-
bution of NOTCH as a key mediator of contact-dependent 
secondary senescence, or juxtacrine senescence. Provided 
that the canonical action of NOTCH in mediating cell-to-
cell signalling has critical implications in diseases such as 
cancer, the idea that senescence can spread by NOTCH1 sig-
nalling via direct cell-to-cell contact is an appealing notion 
that has only been pursued recently. As discussed earlier, the 
role of NOTCH signalling in senescence has been explored 
in NIS as a primary cell-autonomous process [21]. The same 
study also further revealed the non-cell-autonomous effects 
of NIS cells through a cell-contact dependent mechanism 
that propagates secondary senescence in their surrounding 
environment. Through ectopic expression of N1ICD, the 
primary senescent N1ICD-expressing cells were able to 
mediate lateral transmission of senescence to their neigh-
bouring naïve cells in a JAG1-dependent manner. Inhibition 
of NOTCH signalling consequently compromised non-cell-
autonomous secondary senescence. NOTCH-mediated jux-
tacrine senescence was further shown in a subsequent study 
to non-autonomously regulate chromatin structure in normal 
adjacent cells, repressing SAHF formation by suppressing 
expression of HMGA genes [23].
Despite the clear evidence of NOTCH signalling in facili-
tating juxtacrine secondary senescence, the nature of the 
secondary senescence population itself was not explored or 
characterised. The important question is whether NOTCH 
acts as a senescence inducer in neighbouring naïve cells that 
have not experienced oncogenic insults, in addition to SASP, 
particularly in the context of primary OIS cells that do not 
undergo ectopic activation of NOTCH. Recent work has 
presented a conceptual advance that primary and second-
ary senescence can be viewed as two distinct transcriptional 
termini and that NOTCH is an important effector of second-
ary senescence [54] [Fig. 2]. Single-cell RNA sequencing 
approaches were used to investigate the heterogeneity within 
OIS and identified two major transcriptional endpoints, one 
being a primary senescent population and the other a sec-
ondary senescent population. In contrast to the traditional 
view that paracrine senescence is the only mediator of sec-
ondary senescence in OIS, our downstream transcriptomic 
analyses revealed a pronounced enrichment of NIS signature 
in the secondary senescence population, suggesting NOTCH 
as a potent mediator. The requirement for NOTCH signalling 
for secondary senescence induction was confirmed in vitro 
through a co-culture system between NOTCH-incompetent 
cells and primary OIS cells. As opposed to the outcome 
of pure primary NIS, where the pro-inflammatory SASP 
components are suppressed and fibrillar collagens induced, 
the OIS-mediated secondary senescent cells showed both 
expression of SASP factors and induction of fibrillar col-
lagens. Distinguishing the complex crosstalk between two 
modes of secondary senescence was only possible at sin-
gle cell resolution. To further dissect the contribution of 
NOTCH to the activation of secondary senescence, second-
ary cells with impaired NOTCH signalling were co-cultured 
with primary OIS cells, and compared with secondary cells 
with intact NOTCH. Gene set enrichment analysis confirmed 
that the NOTCH-compromised cells upregulated the inter-
feron-gamma response and pro-inflammatory factors rela-
tive to the normal secondary cells, suggesting that NOTCH 
signalling blunted the SASP response to a certain extent. 
Furthermore, this study provided in vivo data in secondary 
senescent-induced hepatocytes, which showed upregula-
tion of NOTCH signalling compared to primary senescent 
hepatocytes. This concept was strengthened in an in vivo 
liver cancer model in which the recruitment of immune cells 
was compromised by the lateral transmission of NOTCH1-
mediated senescence [26].
As research on secondary senescence is still in the nascent 
stage, the exact role and biological significance of NOTCH-
mediated juxtacrine senescence and secondary senescence, 
in general, remain elusive. At least, it has become increas-
ingly apparent that throughout the course of OIS, cells 
mature from pre-senescence to complete senescence, under-
going different stages where secondary senescence signals 
are dynamically transmitted to adjacent cells. Principally, 
secondary senescence encompasses both paracrine and 
juxtacrine modalities, but exact nature and timing of their 
operation and regulation is just beginning to emerge. In com-
bination with the proposed model of the transient NOTCH/
TGF-β-dominant secretome in the early phase of OIS and 
pro-inflammatory C/EBPβ-rich SASP in the late phase, the 
results from the single cell RNA-sequencing experiment of 
OIS cells suggest that juxtacrine senescence is predomi-
nantly achieved in the early NOTCH phase, while paracrine 
senescence takes on a more influential role when OIS is 
fully established [26, 27, 54]. The transition between the two 
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phases is largely understudied, nevertheless. To understand 
whether and how secondary senescence is shaped by such a 
complex and dynamic programme, future investigation must 
include novel approaches that can dissect the relative con-
tribution of each phase towards the induction of secondary 
senescence as well as determine their interactions with one 
another. Another tantalising area of study is to test whether 
the secondary paracrine wave of OIS also holds true in other 
senescence settings, from replicative senescence to DNA 
damage-induced senescence. The following question will 
then be asked: does the absence or presence of secondary 
senescence serve as a differentiating marker between OIS 
and other types of senescence, and does it have any physi-
ological implications?
From a biological point of view, a conjectural interpre-
tation of the composite transcriptional NOTCH and SASP 
signature in secondary senescence represents a fine control 
of cell proliferation activity and immune surveillance in 
the senescent milieu. Dysregulation of the initial stage of 
NOTCH-mediated senescence might promote tissue fibro-
sis through overexpression of collagen. Likewise, long-term 
persistence of inflammation or downregulation of NOTCH 
signalling in the late SASP-rich phase would in turn result 
in immunosuppression in the cellular neighbourhood and 
Fig. 2  Schematic representation 
of how secondary senescence 
is established from primary 
senescence. There are two 
forms of primary senescence: 
oncogene-induced senescence 
(OIS) and Notch-induced senes-
cence (NIS). These primary 
senescent cells can further 
trigger secondary senescence 
in their neighbouring cells in 
the process called secondary 
senescence, which can be medi-
ated by cell-to-cell contact and/
or paracrine transmission of 
senescence-associated secretory 
phenotype (SASP). Notch-
dominant secondary senescence 
relies on expression of growth 
factors and TGFβ as well as the 
induction of fibrillar collagens. 
SASP-dominant secondary 
senescence, on the other hand, 
is driven by release of proin-
flammatory cytokines, expres-
sion of C/EBPβ and spread of 
SASP. Both Notch-driven and 
SASP-driven secretome profiles 
are found to contribute to a pop-
ulation of secondary senescent 
cells. Under normal conditions, 
the combined consequences of 
paracrine and juxtacrine signal-
ling include the recruitment of 
immune cells and clearance of 
senescent cells. Here, primary 
and secondary senescent cells 
are viewed as functionally 
distinct endpoints
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decrease the efficiency of immune-clearance of tumour-
prone senescent cells, thereby favouring pre-neoplastic 
transformation in normal bystander cells [55]. In this con-
text, alterations or disruption to the dynamic transition from 
the TGFβ-driven to the C/EBPβ-driven SASP secretomes 
might explain the dual and pleiotropic role of OIS in cancer 
formation. Therefore, under normal physiological condi-
tions, the ultimate effects of juxtacrine senescence might 
lead to a scenario where the spread of senescence within a 
tissue is limited locally once secondary senescence is estab-
lished [Fig. 3]. This local containment of senescence spread 
would guarantee tissue homeostasis and might be beneficial 
for immune cells to effectively eliminate detrimental senes-
cent cells from that local environment. Verification of this 
functional model would be assisted by evidence in vitro and 
in vivo showing that NOTCH-enriched secondary senescent 
cells represent not a transient but a definitive transcriptional 
endpoint from which no further senescence is propagated 
and meaningful and effective immune-clearance can arise. 
Since primary senescence is widely recognised to suppress 
tumours, stimulate wound healing and play a role in the age-
ing process, it will be tantalising to investigate the function 
of secondary juxtacrine senescence in the contexts of tumour 
suppression, wound healing and ageing phenotypes in future 
studies.
Transmission of senescence in organs
Senescent cell accumulation takes place in many tissues and 
organs, including the liver and the kidney, often in asso-
ciation with a functional decline and homeostatic capac-
ity of those organs [56]. In hepatocellular senescence, the 
hepatocytes gradually lose regenerative potential and have 
increased susceptibility to chronic damage, cirrhosis, fibrosis 
and hepatocellular carcinoma [57, 58].
Compelling evidence suggests that hepatocytes under-
going primary senescence upon acute liver injury in the 
AhCre-Mdm2fl/fl model can spread the senescence pheno-
type to nearby normal hepatocytes via SASP and the reliance 
on TGFβ signalling [52]. The TGFβ-dependent transmission 
of senescence was also reported in senescent cholangiocytes, 
which induced secondary senescence in normal surrounding 
hepatocytes while inhibition of TGFβ disrupted the transfer 
of senescence and restored liver function [59]. Combined 
with our recent in vivo liver data that revealed NIS signa-
ture in secondary senescent hepatocytes [54], it is possible 
that transmission of senescence in the liver is synergistically 
achieved by both paracrine induction and juxtacrine events.
The kidney is also known to be affected by constituents 
of SASP [60–62]. A variety of cell types in the kidney such 
as renal epithelial, endothelial, tubular and glomerular cells 
undergo age-associated changes over time with simultaneous 
upregulation of senescence markers [56, 63, 64]. Charac-
teristics of aged kidneys include glomerulosclerosis, inter-
stitial fibrosis and nephron atrophy, which contribute to an 
increased risk of chronic kidney injury and ultimately acute 
renal failure [65, 66]. In a mouse model of renal fibrosis, 
attenuation of p16 led to a decrease in interstitial fibrosis 
and nephron atrophy after ischemia–reperfusion injury, 
suggesting that inhibition of senescence could benefit renal 
function. This was further shown in transgenic mice where 
targeted ablation of p16-positive senescent cells attenuated 
glomerulosclerosis and helped to maintain healthy blood 
urea nitrogen levels [46]. Mounting evidence has shown 
that during chronic kidney disease SASP factors are secreted 
from endothelial cells and macrophages [60]. Consistently, 
a knockdown of plasminogen activator inhibitor-1 (PAI-1), 
a SASP factor, attenuated the formation of renal fibrosis 
upon kidney injury [67]. Interestingly, NOTCH signalling 
has also been implicated in senescent kidney cells. In mouse 
based study, the prolonged activation of tubular epithelial 
Fig. 3  Schematic representation of the local containment of second-
ary senescence. Since the Notch ligand JAG1 is upregulated specifi-
cally in primary senescence cells, it could be possible that the sec-
ondary spread of senescent cells can be contained locally, as opposed 
to the senescence process expanding endlessly once established. Sec-
ondary senescent cells, which express low levels of the ligand JAG1, 
will not be able to induce further senescence responses. Such a local 
containment might allow unwanted senescent cells to be efficiently 
eliminated by the immune system
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NOTCH1 diminished the regenerative potential of the kid-
ney and was associated with the pro-senescent phenotype 
[68]. Yet not much is known about the establishment of sec-
ondary senescence by juxtacrine NOTCH signalling in the 
context of the senescent kidney. It will be useful and impor-
tant to investigate the transcriptomes of senescent kidney 
cells and determine if primary and secondary senescence 
signatures can be distinguished and to what extent NOTCH 
and SASP contribute to secondary senescence.
Concluding remarks
Oncogene-induced senescence unmistakably represents a 
tumour suppressor mechanism, but our understanding of its 
induction and establishment is not yet complete. The hetero-
geneity of the OIS programme is only beginning to be elu-
cidated through the use of single-cell technologies. Among 
the key questions that need to be addressed are whether all 
cells respond similarly to the same oncogenic activation 
and whether the same oncogenic insult always results in a 
heterogenous OIS population. We have summarised current 
evidence for a functional heterogeneity in the senescence 
response in a recent review [69]. Studies of OIS cells and 
their transcriptomes in vitro and in vivo have unmasked a 
complex regulation of their dynamic and heterogeneous 
nature. Rather than being a stable entity following its trig-
gers, OIS is endowed with both autonomous and non-cell 
autonomous activities, which allow OIS cells to interact with 
their neighbouring normal or transformed cells. One major 
effect of this interaction is the paracrine transmission of the 
senescent phenotype, largely mediated by secretion of a vast 
array of SASP factors, contributing to a secondary induction 
of senescence in the surrounding environment.
OIS, primary or secondary, is traditionally believed to 
have only one functional endpoint, but recent research has 
favoured the notion that primary and secondary senescent 
cells are in fact functionally distinct stages of OIS. Further-
more, transcriptomic analyses have challenged the prevailing 
view that paracrine induction of senescence is the only main 
mediator of secondary senescence in OIS, with juxtacrine 
NOTCH signalling emerging as a synergistic driver of sec-
ondary senescence. This means that OIS is a far more com-
plex state than previously anticipated, with autocrine, par-
acrine and juxtacrine signalling pathways being at play. The 
precise mechanisms that govern the induction of senescence 
through paracrine or juxtacrine signalling, however, remain 
elusive. It is highly possible that the secondary induction of 
OIS is dictated by the dynamically spatiotemporal patterns 
of the senescence-associated secretomes as well as cell-
to-cell interactions, which in turn shape the varied quality, 
quantity, output and changes of OIS functionality. To obtain 
a better insight into the molecular basis for the regulation of 
secondary senescence, novel technologies such as single-cell 
transcriptomics and genomics will prove valuable in iden-
tifying and characterising more subtle events taking place 
over the course of OIS, primary or secondary. Accordingly, 
investigating the heterogeneity of a senescent cell popula-
tion is one approach to uncovering the actual contribution of 
each mode of senescence transmission, and will significantly 
highlight directions for the strategic development of new and 
specific drugs that target deleterious senescent cells.
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